Proactive Investors - Run By Investors For Investors

Seelos Therapeutics to meet with FDA on its proof-of-concept ketamine study to treat depression

Seelos Therapeutics Inc (NASDAQ:SEEL) CEO Raj Mehra tells Proactive Investors the New York-based biopharma is scheduled to meet with the FDA to design a proof-of-concept study linked to its intranasal ketamine depression treatment aimed at patients with post-traumatic stress disorder (PTSD) at imminent risk of suicide.

Dr Mehra also commented on the positives from President Donald Trump's recent announcement that he would he would be willing to help the Department of Veteran Affairs with negotiating the price of a new Johnson & Johnson (NYSE:JNJ) ketamine depression drug.

 
View full SEEL profile View Profile

Seelos Therapeutics Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use